3 terminated, 1 completed, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow this drug Literature Review of OTX015 trials Research Report on OTX015
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) Birabresib Dose 20 mg - AML Including AML de Novo and AML Secondary to MDS, DLBCL | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 9 | 2016-05-19 | 2022-09-13 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) Birabresib - NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 13 | 2016-05-04 | 2021-01-27 |
| A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) OTX015, Vidaza (azacitidine) - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-01-01 | 2016-09-01 | |
| A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) Birabresib - Glioblastoma Multiforme | Phase 2 | Terminated | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 12 | 2014-10-29 | 2021-01-26 |
| A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) OTX015/Birabresib - Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 141 | 2012-12-14 | 2021-01-26 |
Leukemia, Myeloid, Acute (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Triple Negative Breast Neoplasms (1)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Merck Sharp & Dohme LLC (2)
PMID 26341814, PMID 27063977, PMID 27063978
2015 (2), 2014 (1)